ATOSSA THERAPEUTICS INC (ATOS)

Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen

SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced an expanded research...

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

SEATTLE, April 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare...

Friday 4/12 Insider Buying Report: ATOS, TRDA

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive...

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and...

ATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023

ATOS stock results show that Atossa Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

ATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Atossa Therapeutics (NASDAQ:ATOS) just reported results for the fourth quarter ...

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024First patient dosed in new Phase 2 breast cancer prevention...

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient

SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the...

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

SEATTLE, March 18, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that on March 15, 2024,...

Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

SEATTLE, March 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical...

Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative...

Atossa stock a new Buy at H.C. Wainwright (NASDAQ:ATOS)

Atossa Therapeutics (ATOS) receives a Buy rating and $4 price target from H.C. Wainwright, due to its breast cancer drug, Z-Endoxifen. Read more here.

Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial

SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative...

Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market

In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for.

Atossa Therapeutics Issues Letter to Shareholders

SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative...

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

SEATTLE, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative...

Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

SEATTLE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative...

Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Achieved significant enrollment milestones in ongoing Phase 2 clinical trialsFour ongoing Phase 2 studies evaluating (Z)-endoxifen, including recently...

Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors

SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative...

Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group

/PRNewswire/ -- Quantum Leap Healthcare Collaborative (QLHC) announces the enrollment launch for the Re-Evaluating Conditions for Active Surveillance...

Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades later

/PRNewswire/ -- Physician-Scientist Dr. Steven Quay, MD, PhD is calling for nutritional guidelines for adolescent girls to reduce processed and fast-food...

Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023

SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative...

Atossa stock jumps 16% in wake of Cantor overweight rating (ATOS)

Atossa Therapeutics (ATOS) shares were up 16% after Cantor Fitzgerald initiated coverage of the stock with an overweight rating, citing upcoming data readouts. Read more here.

Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Achieved significant enrollment milestones in three ongoing Phase 2 clinical trialsBroadened patent protection for proprietary (Z)-endoxifenStrengthened...

Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023

SEATTLE, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative...

Atossa stock gains as Canada clears breast cancer trial

Atossa Therapeutics (ATOS) traded higher Thursday Canada cleared a Phase 2 trial for a breast cancer therapy involving its lead asset (Z)-endoxifen. Read more here.

Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada

SEATTLE, July 20, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative...

Atossa Therapeutics regains compliance with Nasdaq's minimum bid price rule (NASDAQ:ATOS)

Biopharmaceutical company Atossa Therapeutics (ATOS) said on Thursday that it has regained compliance with Nasdaq's minimum closing bid price requirement.

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

SEATTLE, July 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative...

Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial

SEATTLE, July 10, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative...